The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dynamics of HER3 and its correlated gene expression profile in EGFR-mutated NSCLC tumor treated with EGFR-TKI toward enhancing effectiveness of patritumab deruxtecan (HER3-DXd; U3-1402).
 
Kimio Yonesaka
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Nihonkayaku; Takeda
Speakers' Bureau - Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim; Daiichi Sankyo
Patents, Royalties, Other Intellectual Property - Patents pending joint application with Daiichi-Sankyo
 
Junko Tanizaki
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Co. Ltd.; Chugai Pharma; EMD Serono/Merck; Lilly Japan; MSD; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma
Speakers' Bureau - AstraZeneca Japan
 
Osamu Maenishi
No Relationships to Disclose
 
Koji Haratani
Honoraria - AS ONE; AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; MSD; Ono Pharmaceutical
 
Hisato Kawakami
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo Co. Ltd.,; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst)
 
Kaoru Tanaka
Honoraria - AstraZeneca; Bristol-Myers Squibb; Eisai; Kyowa Kirin Co., Ltd.; Merck Serono; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Hidetoshi Hayashi
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Merck Serono; Pfizer; Shanghai HaiHe Pharmaceutical
Research Funding - Abbvie (Inst); AC Medical (Inst); Astellas Pharma (Inst); AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Associates Co., Ltd. (Inst); GlaxoSmithKline (Inst); Japan Clinical Research Operations (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical; Otsuka (Inst); PAREXEL (Inst); Pfizer (Inst); PPD-SNBL (Inst); Quintiles Inc. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
Patents, Royalties, Other Intellectual Property - Sysmex
 
Kazuko Sakai
No Relationships to Disclose
 
Yasutaka Chiba
No Relationships to Disclose
 
Hiroki Goto
Employment - Daiichi Sankyo RD Novare
 
Eri Otsuka
Employment - Daiichi Sankyo RD Novare
 
Hiroaki Okida
Employment - Daiichi Sankyo RD Novare
 
Maki Kobayashi
Employment - Daiichi Sankyo RD Novare
 
Ryoto Yoshimoto
Employment - Daiichi Sankyo RD Novare
 
Masanori Funabashi
Employment - Daiichi Sankyo RD Novare
 
Yuuri Hashimoto
Employment - Daiichi Sankyo
 
Kenji Hirotani
Employment - Daiichi Sankyo Co. LTD.,
 
Takashi Kagari
Employment - Daiichi Sankyo
 
Kazuto Nishio
Speakers' Bureau - Amgen; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Company; Chugai Pharma; Fujirebio; Guardant Health; Janssen; Lilly Japan; Merck; MSD K.K.; Novartis; Otsuka; Pfizer; Roche; Solasia Pharma; SymBio Pharmaceuticals; Takeda; Yakult Honsha
Research Funding - Clinical Research Support Center Kyushu; Nichirei; Nippon Boehringer Ingelheim; North East Japan Study Group; Osaka Minami Hospital; Thoracic Oncology Research Group; West Japan Oncology Group
 
Kazuhiko Nakagawa
Honoraria - 3H Clinical Trial; Amgen; AstraZeneca Japan; Bayer Yakuhin; CareNet; Chugai Pharma; CMIC; CMIC Co., Ltd.; Japan Clinical Research Operations; Kyowa Kirin Co., Ltd.; Kyowa Kirin Co., Ltd.; Life Technologies; Lilly Japan; Medical Mobile Communications; Medical Review Co., Ltd.; Merck; MSD K.K; Neo Communication; Nikkei Business Publications, Inc; Nippon Boehringer Ingelheim; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Taiyo Pharma; Takeda; YODOSHA
Consulting or Advisory Role - Lilly Japan; Ono Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); Covance (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Holdings (Inst); EPS Holdings (Inst); EPS International (Inst); GlaxoSmithKline K.K. (Inst); IQvia (Inst); Janssen (Inst); Japan Clinical Research Operations (Inst); Kissei Pharmaceutical (Inst); Lilly Japan (Inst); Mebix (Inst); Medical Reserch Support (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD K.K (Inst); Nippon Boehringer Ingelheim (Inst); Nippon Kayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); PAREXEL International Corp. (Inst); PPD-SNBL (Inst); PRA HEALTHSCIENCES (Inst); Sanofi (Inst); SRL Diagnostics (Inst); SymBio Pharmaceuticals (Inst); Syneos Health (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Daiichi Sankyo Co., Ltd. (Inst)